Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth

被引:0
作者
Bandola-Simon, Joanna [1 ]
Ito, Yoshinaga [2 ]
Wucherpfennig, Kai W. [3 ,4 ,5 ,6 ]
Roche, Paul A. [1 ]
机构
[1] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
[2] Kyoto Univ, Inst Life & Med Sci, Kyoto 6068507, Japan
[3] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA
[4] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA
[6] Harvard Med Sch, Boston, MA 02115 USA
来源
CELL REPORTS | 2025年 / 44卷 / 01期
基金
美国国家卫生研究院;
关键词
HLA-DR MOLECULES; COMPLEX CLASS-II; T-CELL HELP; DENDRITIC CELLS; DOWN-REGULATION; MELANOMA LESIONS; CATHEPSIN-S; CLIP; EXPRESSION; DM;
D O I
10.1016/j.celrep.2024.115150
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumor-draining lymph node dendritic cells (DCs) are poor stimulators of tumor antigen-specific CD4 T cells; however, the mechanism behind this defect is unclear. We now show that, in tumor-draining lymph node DCs, a large proportion of major histocompatibility complex class II (MHC-II) molecules retains the class II-associated invariant chain peptide (CLIP) fragment of the invariant chain bound to the MHC-II peptide binding groove due to reduced expression of the peptide editor H2-M and enhanced activity of the CLIP-generating proteinase cathepsin S. The net effect of this is that MHC-II molecules are unable to efficiently bind antigenic peptides. DCs in mice expressing a mutation in the invariant chain sequence that results in enhanced MHC-IICLIP accumulation are poor stimulators of CD4 T cells and have diminished anti-tumor responses. Our data reveal a previously unknown mechanism of immune evasion in which enhanced expression of MHC-II-CLIP complexes on tumor-draining lymph node DCs limits MHC-II availability for tumor peptides.
引用
收藏
页数:15
相关论文
共 64 条
  • [11] Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome
    Chamuleau, MED
    Souwer, Y
    van Ham, SM
    Zevenbergen, A
    Westers, TM
    Berkhof, J
    Meijer, CJLM
    van de Loosdrecht, AA
    Ossenkoppele, GJ
    [J]. CANCER RESEARCH, 2004, 64 (16) : 5546 - 5550
  • [12] The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses
    Chaturvedi, P
    Hengeveld, R
    Zechel, MA
    Lee-Chan, E
    Singh, B
    [J]. INTERNATIONAL IMMUNOLOGY, 2000, 12 (06) : 757 - 765
  • [13] SPECIFICITY AND PROMISCUITY AMONG NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR ALLELES
    CHICZ, RM
    URBAN, RG
    GORGA, JC
    VIGNALI, DAA
    LANE, WS
    STROMINGER, JL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01) : 27 - 47
  • [14] PREDOMINANT NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR1 ARE DERIVED FROM MHC-RELATED MOLECULES AND ARE HETEROGENEOUS IN SIZE
    CHICZ, RM
    URBAN, RG
    LANE, WS
    GORGA, JC
    STERN, LJ
    VIGNALI, DAA
    STROMINGER, JL
    [J]. NATURE, 1992, 358 (6389) : 764 - 768
  • [15] Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter
    Choi, Young-Eun
    Yu, Ha-Nul
    Yoon, Cheol-Hee
    Bae, Yong-Soo
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (03) : 858 - 868
  • [16] Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL)
    Cycon, Kell A.
    Rimsza, Lisa M.
    Murphy, Shawn P.
    [J]. EXPERIMENTAL HEMATOLOGY, 2009, 37 (02) : 184 - 194
  • [17] HLA-DM INDUCES CLIP DISSOCIATION FROM MHC CLASS-II ALPHA-BETA DIMERS AND FACILITATES PEPTIDE LOADING
    DENZIN, LK
    CRESSWELL, P
    [J]. CELL, 1995, 82 (01) : 155 - 165
  • [18] Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
    Dhatchinamoorthy, Karthik
    Colbert, Jeff D.
    Rock, Kenneth L.
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [19] Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery
    Fuchs, Natalie
    Meta, Mergim
    Schuppan, Detlef
    Nuhn, Lutz
    Schirmeister, Tanja
    [J]. CELLS, 2020, 9 (09) : 1 - 17
  • [20] Dendritic Cells and Cancer Immunity
    Gardner, Alycia
    Ruffell, Brian
    [J]. TRENDS IN IMMUNOLOGY, 2016, 37 (12) : 855 - 865